A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)

Phase 2

Not yet recruiting

• Conditions: Metastatic Colorectal Cancer (CRC)
• Interventions: Drug: Cetuxima-β; Drug: Envafolimab; Drug: mFOLFOX6

• Registration Number: NCT06959693
• Lead Sponsor: Sun Yat-sen University

Brief Summary

This is a prospective randomized controlled Phase Ⅱ/Ⅲ Clinical study to evaluate the clinical efficacy and safety of Envafolimab combining with Cetuximab -β and mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)

Detailed Description

Patients diagnosed with unresectable, microsatellite - stable (MSS), RAS/BRAF wild - type metastatic colorectal adenocarcinoma who have not received prior systemic anti-neoplastic therapy for metastatic or recurrent lesions will be included in this study.

In the Phase II study, approximately 186 patients will be enrolled, with 93 assigned to the experimental group and 93 to the control group. In the Phase III study, around 404 patients will be recruited, with 202 allocated to the experimental group and 202 to the control group.

Eligible patients will undergo a screening period of up to 28 days, followed by a treatment period consisting of 2 - week cycles for a maximum duration of 2 years. Subsequently, a follow - up period will be implemented, which includes a safety follow - up and survival follow - ups conducted every 12 weeks.

Study Timeline

• Status Verified: 2025-04
• Study First Submitted: 2025-04-28
• Study First Submitted QC: 2025-04-28
• Last Update Submitted: 2025-04-28
• Study First Posted: 2025-05-06
• Last Update Posted: 2025-05-06
• Study Start: 2025-06-01
• Primary Completion: 2028-09-30
• Study Completion: 2030-06-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 590

Inclusion Criteria

• Patients are eligible for the study if they meet all of the following criteria:

  1. Prior to enrollment, the participant is required to sign a written informed consent form.

  2. Participants should be above 18 years，regardless of gender.

  3. Histopathologically confirmed untreated advanced colorectal adenocarcinoma.

  4. Tumors with RAS (KRAS, NRAS, HRAS) and BRAF wild-type, MSS phenotype, excluding appendiceal or anal cancer. All listed codons must be wild-type: KRAS: Exons 2, 3, 4 (Codons 12, 13, 59, 61, 117, 146) ; NRAS: Exons 2, 3, 4 (Codons 12, 13, 59, 61, 117, 146)

  5. Imaging (enhanced CT/MRI/PET-CT) confirms advanced/metastatic colorectal cancer with measurable lesions according to RECIST v1.1.

  6. No prior systemic therapy for advanced/metastatic colorectal cancer, including chemotherapy, EGFR inhibitors (cetuximab, panitumumab), VEGF inhibitors (bevacizumab), and immune checkpoint inhibitors (anti-PD-1/PD-L1/CTLA-4). Adjuvant/neoadjuvant chemotherapy within 6 months before recurrence/metastasis is considered first-line therapy.

  7. ECOG PS score 0-1.

  8. Expected survival >12 weeks.

  9. Adequate organ function (without blood component or growth factor use within 14 days):

     Hematology:Neutrophils ≥1.5×10⁹/L, platelets ≥100×10⁹/L, hemoglobin ≥90 g/L. Liver/kidney function: SCr ≤1.5×ULN or creatinine clearance ≥50 ml/min, TBIL ≤1.5×ULN, AST/ALT ≤2.5×ULN (≤5×ULN if due to liver metastasis), urine protein <2+ (≤1g/24h if ≥2+).

  10. Normal coagulation, no active bleeding/thrombosis: INR ≤1.5×ULN, APTT ≤1.5×ULN, PT ≤1.5×ULN.

  11. Non-surgically sterile women of childbearing potential must use contraception during and 3 months after treatment; serum/urine HCG negative within 7 days before enrollment; not breastfeeding. Non-surgically sterile men must use contraception with partners during and 3 months after treatment.

  12. Willing participant with good compliance for safety and survival follow-up.

Exclusion Criteria

• Patients will be excluded from the study if they meet any of the following exclusion criteria:

  1. Other malignancies in the past or current (excluding cured basal cell carcinoma or cervical carcinoma in situ).
  2. Current duodenal ulcer, ulcerative colitis, intestinal obstruction, or other GI conditions that may cause bleeding or perforation, as judged by the investigator.
  3. Patients with symptomatic pleural, peritoneal, or pericardial effusions requiring treatment.
  4. History of allergy to monoclonal proteins or any component of the study drugs.
  5. Oral traditional Chinese medicine, immunomodulators within 2 weeks, or radiotherapy within 4 weeks before treatment.
  6. Thyroid dysfunction that is uncontrolled by medication.
  7. Uncontrolled hypertension despite receiving optimal treatment (systolic BP>150 mmHg or diastolic BP>90 mmHg).
  8. Uncontrolled cardiac conditions: (1) NYHA Class II+ heart failure; (2) unstable angina; (3) myocardial infarction within 1 year; (4) clinically significant arrhythmias requiring treatment.
  9. Active autoimmune disease or a history of such diseases.
  10. Immunosuppressants, systemic, or absorbable topical steroids for immunosuppression (>10 mg/day prednisone or equivalent) within 2 weeks before enrollment.
  11. CNS metastases.
  12. Active infection or unexplained fever>38.5°C during screening or before first dose (tumor-related fever is acceptable).
  13. History or current evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-induced pneumonia, or severe pulmonary dysfunction.
  14. Congenital or acquired immunodeficiency, such as HIV infection, or active hepatitis (elevated transaminases not meeting inclusion criteria, HBV DNA≥1000 IU/ml, HCV RNA≥1000 IU/ml).
  15. Live vaccine administration within 4 weeks before first dose or planned during the study.
  16. History of psychiatric drug abuse, alcoholism, or drug addiction.
  17. Pregnant or breastfeeding women, or those planning pregnancy during the trial.
  18. Any other factor that may lead to premature study discontinuation, as judged by the investigator.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Envafolimab combining with Cetuximab -β and mFOLFOX6	Cetuxima-β	-
Envafolimab combining with Cetuximab -β and mFOLFOX6	Envafolimab	-
Envafolimab combining with Cetuximab -β and mFOLFOX6	mFOLFOX6	-
Cetuximab -β and mFOLFOX6	Cetuxima-β	-
Cetuximab -β and mFOLFOX6	mFOLFOX6	-

Primary Outcome Measures

Name	Time	Method
Progressin Free Survival，PFS	Time Frame: from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 3 years	Progression-free survival based on RECIST v1.1

Secondary Outcome Measures

Name	Time	Method
OS，Overall survival	from the date of first dose unitl the date of death from any cause，assessed up to 3 years
ORR， Objective response	up to 3 years	Objective response rate based on RECIST v1.1
DCR， Disease control rate	up to 1 year	the proportion of patients with the best overall response of CR, PR, or stable disease (SD)
NED Rate， No Evidence of Disease Rate	up to 3 years	The proportion of participants with no evidence of disease after treatment, as determined by current assessments (pathological, imaging, and molecular biology). NED includes complete response (CR), R0 resection, or other local treatments, such as radiofrequency, microwave, or cryoablation (which can be combined with surgery), that eliminate the tumor.
Safety(Adverse Event (AE) Incidence)	up to 3 years	Adverse Event (AE) Incidence

Trial Locations

Locations (1)

Medical Oncology,Sun Yat-sen University Cancer Center; 🇨🇳 Guangzhou, Guangdong, China